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3Department of Pathology, Konkuk University School of Medicine, Seoul, Republic of KoreaClevudine (L-FMAU) is a thymidine L-nucleoside analogue that was recently introduced for the treatment of chronic
hepatitis B virus infection. Previous studies showed that clevudine has potent and sustained antiviral activity without caus-
ing viral resistance. No severe adverse event occurred during clinical trials. We describe two cases of drug-induced myop-
athy during long-term treatment of chronic hepatitis B with clevudine.
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Clevudine [L-FMAU, (1-(2-ﬂuoro-5-methyl-b,L-ara-
binofuranosyl) uracil)] is a pyrimidine L-nucleoside ana-
logue with potent and sustained antiviral activity against
hepatitis B virus (HBV) [1–3]. It is an enantiomer of
[D-FMAU, (1-(2-ﬂuoro-5-methyl-b,D-arabinofuranosyl)
uracil)] and is structurally related to ﬁaluridine
[D-FIAU, (1-(2-deoxy-2-ﬂuoro-b, D-arabinofuranosyl)
iodouracil)], lamivudine and telbivudine [4]. Although
previous studies have demonstrated the antiviral eﬃcacy0168-8278/$36.00  2009 European Association for the Study of the Liver.
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D-arabinofuranosyl) uracil); D-FIAU, (1-(2-deoxy-2-ﬂuoro-b, D-arabi-
nofuranosyl) iodouracil); ALT, alanine aminotransferase; EMG, elec-
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chemoembolization.and safety of clevudine during and after short-term
treatment, corresponding data on long-term treatment
with clevudine is limited.
Antiviral nucleoside/nucleotide analogue-induced
myopathies were reported for ﬁaluridine treatment for
chronic hepatitis B and zidovudine treatment for HIV
[5,6]. The mechanism by which myopathy is induced
by these drugs involves inhibition of mitochondrial
DNA polymerase c, which results in mitochondrial
DNA dysfunction in vitro [7]. Recently, cases of telbivu-
dine-induced myopathy have been reported. However,
there were no severe adverse eﬀects, including myotoxic-
ity, in clinical clevudine trials [8–12].
We describe clinical features and pathologic ﬁndings
for two patients with myopathy who received clevudine
therapy for chronic hepatitis B. To our knowledge, this
is the ﬁrst report of clevudine-related myopathy that is
not associated with mitochondrial damage.2. Case report
Case 1. A 42-year-old female who received clevudine
therapy for chronic hepatitis B presented with progres-
sive weakness of both lower legs and had experienced
diﬃculty in chewing over the previous four months.
She had chronic hepatitis B for more than 10 yearsPublished by Elsevier B.V. All rights reserved.
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16 months. She had not taken any other medication dur-
ing the clevudine therapy. After clevudine therapy, her
HBV DNA level decreased to an undetectable level
and her serum ALT level normalized. The patient suf-
fered from progressive and generalized weakness, espe-
cially of the legs, and experienced diﬃculty in climbing
stairs. However, she did not have dysphagia, cramps
or sensory symptoms. She exhibited motor weakness
(grade 4) of the hip ﬂexor making her diﬃcult to stand
up from the sitting position, but there was no sign of
abnormal deep tendon reﬂex, muscle atrophy or hyper-
trophy on physical examination. Laboratory analyses
showed an elevated creatine kinase level (220 U/L),
whereas lactic acid concentration was within the normal
range (Table 1, Case 1). Tests for serum autoimmune
markers (anti-nuclear antibody, anti-double-strand-DNA
antibody, acetylcholine receptor antibody, and anti-Jo1
antibody) were all negative. Tests for serum tumor
markers (alphafetoprotein, carcinoembryonic antigen,
CA19-9, and CA-125) were all within the normalTable 1
Laboratory results in the two cases with clevudine myopathy.
Patient 1
Before clevudine
therapy
(April 26, 2007)
Diagnosis of
myopathy
(July 29, 2008)
Last
follow-up
(January 1
2009)
WBCs (109/L) 5760 4.53 4.83
Hemoglobin (g/dL) 13.1 12.6 14.0
Platelets (109/L) 170 162 187
Prothrombin time (INR) – 1.11 1.08
Total bilirubin (g/dL) 0.6 0.4 0.7
AST (IU/L) 110 40 26
ALT (IU/L) 172 32 24
Albumin (lg/dL) 4.5 3.9 4.3
LDH (IU/L) 154 650 432
Creatinine (mg/dL) 0.6 0.7 0.8
Creatine kinase (U/L) 43 220 96
Myoglobin (ng/mL) – 120.6 –
Aldolase (U/L) – 8.3 –
Calcium (mg/dL) 9.5 8.9 9.0
Phosphate (mg/dL) 4.3 3.6 4.6
Lactic acid (mmol/L) – – 1.7
HbsAg Positive Positive Positive
Anti-HBs Negative Negative –
HbeAg Negative Negative Negative
Anti-HBe Positive Positive Positive
HBV DNA (copies/mL) 3.22  107 <300 <300
HCV antibody Negative Negative –
HIV antibody – Negative –
Alphafetoprotein (ng/mL) 3.0 2.99 2.20
Abbreviations used: AST, aspartate aminotransferase; ALT, alanine aminot
antigen; Anti-HBs, anti-hepatitis B surface antibody; HbeAg, hepatitis B e a
virus DNA; –, not available.range. Stool occult blood test was negative. Abdom-
inal sonography and gastroduodenoscopy showed no
malignant lesion. Electromyography (EMG) showed a
few positive sharp waves or ﬁbrillation potentials with
early recruitment of myopathic motor unit action poten-
tials (MUAPs) in the right deltoid, vastus medialis,
gastrocnemius, lumbar paraspinal and orbicularis oris
muscles, which is consistent with the active stage of
generalized myopathy (Fig. 1A and B). A biopsy speci-
men was taken from the left vastus lateralis muscle.
On light microscopic examination of the specimen, there
was signiﬁcant size variation of myoﬁbers revealing
many degenerating and necrotic myoﬁbers (Fig. 2A).
The necrotic myoﬁbers showed inﬂammatory cellular
inﬁltrate that was mainly composed of macrophages
(Fig. 2A). There were little inﬁltrate of inﬂammatory
cells in perivascular spaces and no endomysial ﬁbrosis.
The speciﬁc ﬁndings of other primary myopathies such
as inclusion myopathy or mitochondrial myopathy were
not observed during the electron microscopic examina-
tion. The patient took 50 mg prednisolone once dailyPatient 2 Normal
reference
range
2,
Before Clevudine
therapy
(May 29, 2007)
Diagnosis of
myopathy
(October 10,
2008)
Last
follow-up
(February 24,
2009)
4.64 2.03 2.92 4  10
13.0 12.7 12.5 11.5  14.5
105 99 86 140  400
1.08 1.10 1.11 0.8  1.2
0.5 0.7 0.6 0.2  1.2
59 111 59 7  38
39 59 35 4  43
4.0 3.8 4.0 3.3  5.3
433 1403 430 263  450
0.9 0.6 0.7 0.6  1.3
69 526 68 29  145
– – – 116.3
– 33.3 – 7.6
9.1 9.7 9.6 8.0  10.8
4.2 4.5 4.2 2.5  5.5
– – – 0.5  2.2
Positive – – –
Negative – – –
Positive Negative Positive –
Positive Positive Positive –
6.23  105 <300 <300 300 copies/mL
(detect limit)
Negative – – –
Negative – – –
2.83 43.12 1.79 7.0
ransferase; LDH, lactate dehydrogenase; HBsAg, hepatitis B surface
ntigens; Anti-Hbe, anti-hepatitis B e antibody; HBV DNA, hepatitis B
Fig. 1. Electromyographic ﬁndings in right vastus medialis muscle of Case 1. (A) Abnormal spontaneous activities and (B) low amplitude, highly
polyphasic motor unit action potentials with muscle contraction were compatible with myopathic changes.
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roid treatment, her serum creatine kinase level increased
to 750 U/L and there was no clinical improvement in the
muscle weakness. At that stage, we were unaware of the
association between myopathy and long-term clevudine
use. Both clevudine and prednisolone were withdrawn
because of the possibility of drug-induced myopathy.
Her creatine kinase level subsequently normalized to
117 U/L two months after clevudine withdrawal. Her
clinical symptoms subsequently improved to the extent
that she could easily climb stairs (Fig. 3A).Fig. 2. Muscle biopsy specimens. (A) The muscle biopsy specimen from Case
inﬁltration. Black arrows indicate macrophage inﬁltrate in the necrotic myoﬁb
200). (B) The muscle biopsy from Case 2 shows a severely necrotic myoﬁber in
(haematoxylin–eosin-stained paraﬃn section; original magniﬁcation, 200). (C
myoﬁber (arrow) with severe degeneration of subcellular organelles compar
suggestive of mitochondrial myopathy is identiﬁed (inset, left lower).Case 2. A 45-year-old female with chronic hepatitis B
and hepatocellular carcinoma (HCC) was admitted for
combined transarterial chemoembolization (TACE)
and radiofrequency ablation treatment for recurrent
HCC. She had undergone hepatic segmentectomy for
HCC seven years previously and had undergone TACE
15 months previously. She had taken 30 mg of clevudine
once daily for 13 months for treatment of chronic hepa-
titis B with high viraemia (6.23  105 copies/mL, Cobas
Amplicor HBV Monitor, Roche). Her serum HBV
DNA level decreased to an undetectable level and1 revealed many degenerating and necrotic myoﬁbers with macrophage
ers (haematoxylin–eosin-stained paraﬃn section; original magniﬁcation,
dicated by black arrow compared with the adjacent intact other myoﬁbers
) Electron micrograph of a muscle biopsy from Case 2 showed a necrotic
ed with the adjacent intact myoﬁber (). No mitochondrial alteration
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However, she experienced weakness of both legs for
two months. She could not climb stairs and struggled
to get to her feet. She did not take any other medication
or undergo chemotherapy during the clevudine therapy.
On neurological examination, she showed Gowers’
maneuver using her hands and arms to stand up her
body from a squatting position. Muscle strength of both
distal legs was normal. Her serum creatine kinase level
on admission (526 U/L) was markedly elevated com-
pared with baseline (69 U/L) and peaked at 1259 U/LFig. 3. Changes in serum creatine kinase level and HBV DNA for two pati
symptoms 12 months after starting clevudine treatment and was diagnosed w
administered for the myopathy. Clevudine and prednisolone treatment were disc
there was no clinical improvement in muscular symptoms. Two months later, she
creatine kinase were normal. (B) Case 2 experienced muscle weakness nine mon
doctor until she was admitted to the hospital for treatment of recurrent HCC. D
clevudine was replaced with entecarvir. One month later, she reported an impr
clevudine; ETV, entecarvir; Pd, prednisolone; RFA, radiofrequency ablation; T(Table 1, Case 2). Tests for serum autoimmune markers
(anti-nuclear antibody, anti-double-strand-DNA anti-
body, acetylcholine receptor antibody, and anti-Jo1
antibody) showed all negative. Serum alphafetoprotein
increased to 42.12 ng/ml, however, serum carcinoembry-
onic antigen, CA19-9, and CA-125 were within the nor-
mal range. The Papanicolaou smear screening test for
cercvical cancer showed no malignant cell. Computed
tomographic scans of abdomen and pelvis only showed
an 8 mm sized marginal recurrence of hepatocelluar
carcinoma. No malignant lesion was present on theents who were treated with clevudine. (A) Case 1 exhibited myopathic
ith myopathy 16 months after beginning treatment. Steroid was then
ontinued 18 months after commencement of clevudine treatment because
reported an improvement in the muscle weakness, and the levels of serum
ths after clevudine treatment. She did not report the general weakness to
rug-induced myopathy was diagnosed after 13 months of medication and
ovement in muscle power, and her creatine kinase level decreased. CLV,
ACE, transarterial chemoembolization.
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EMG. A muscle biopsy was performed on the vastus
lateralis muscle and it showed many regenerating and
degenerating atrophic myoﬁbers including many necro-
tic myoﬁbers inﬁltrated by macrophages under light
microscopic examination (Fig. 2B). The necrotic myoﬁ-
bers revealed degenerated cytoplasmic organelles and no
signiﬁcant alteration of mitochondria is noted under the
electron microscopic examination (Fig. 2C). Selective
type 2 ﬁbre atrophy was evident after staining for myo-
sine ATPase and nicotinamide adenine dinucleotide-tet-
razolium reductase. The pathologic features indicative
of neurogenic, myogenic or metabolic aetiologies,
including mitochondrial myopathy were not observed
in the muscle biopsy specimen. Clevudine was switched
to entecarvir (0.5 mg/d). The muscle weakness disap-
peared one month after clevudine withdrawal and the
creatine kinase level decreased to 68 U/L at ﬁve months
after clevudine withdrawal (Fig. 3B).3. Discussion
Clevudine is a nucleoside analogue of the unnatural
L-conﬁguration and has potent anti-HBV activity
in vitro and in vivo and a favourable toxicity proﬁle in
all species tested [1–3]. In phase II clinical studies, clevu-
dine exhibited potent antiviral activity, was well toler-
ated and had no dose-limiting toxicity [8]. The lack of
cytotoxicity reﬂects the inability of human cellular
DNA polymerases a, b, c and d to utilize the 50-triphos-
phate moiety of clevudine as a substrate. Moreover,
clevudine was found to have no eﬀect on mitochondrial
structure, DNA content, or function in animal and
in vitro studies [2,13]. None of the many clinical clevu-
dine trials reported severe adverse eﬀects, including
myotoxicity [8–12]. Clevudine is a unique antiviral
nucleotide analogue because its antiviral activity persists
after discontinuation of therapy, as demonstrated by
in vitro and in vivo trials [3,9–11]. Therefore, it is a prom-
ising treatment option for chronic HBV infection [14].
To date, the results of ﬁve clinical trials on clevudine
therapy have been published, including phase II studies
that showed that there were no serious adverse events
after treatment for 24 weeks [8–12]. Although it was
approved for the treatment of chronic HBV infection
in South Korea in November 2006, long-term data on
its safety and antiviral eﬃcacy are limited.
We observed two cases of myopathy during clevudine
therapy for chronic hepatitis B. The clinical symptoms
of myopathy developed after 12 and 10 months of
clevudine treatment, respectively. A diagnosis of clevu-
dine-inducedmyopathy wasmade 18 and 13months after
commencing clevudine treatment, respectively. Levels of
serum creatine kinase and lactate dehydrogenasewere ele-
vated, but lactic acidosis did not occur. TheEMGﬁndingswere consistent with those of chronic myopathy and there
was no evidence of nerve damage. Muscle biopsies
revealed necrosis ofmyoﬁbers and inﬂammatory cell inﬁl-
tration, but the electron-microscopic examination did not
show evidence of mitochondrial damage. The muscle
biopsy features are similar to those of steroid-induced
myopathy in toxic myopathies [15,16]. The clinical and
laboratory ﬁndings showed no evidence of myasthenia
gravis, polymyositis associated with autoimmune
diseases, dermatomyositis, inclusion body myositis or
muscle weakness by paraneoplastic syndrome. The mus-
cle-related symptoms in the cases resolved after cessation
of clevudine treatment. Taken together, the muscle dam-
age was diagnosed as clevudine-induced myopathy.
Nucleoside/nucleotide analogue-induced myopathy
occurs during treatment with ﬁaluridine for chronic hep-
atitis B and treatment with zidovudine for HIV [5,6].
These drugs induce mitochondrial DNA dysfunction
by inhibiting mitochondrial DNA polymerase c [7].
Even though ﬁaluridine treatment caused no serous
adverse events in animal and preliminary studies, it
has been reported that most chronic hepatitis B patients
who are treated with ﬁaluridine develop severe myopa-
thy, lactic acidosis and eventually die [5]. Recently, the
phase III GLOBE study reported three symptomatic
myopathic cases out of 680 patients who received tel-
bivudine. This study also showed that an adverse event,
a grade 3 or 4 elevation in serum creatine kinase level,
occurred in 9% of patients receiving telbivudine [17]. A
Chinese study showed that ﬁve of 105 chronic hepatitis
B patients who received telbivudine treatment developed
clinical myopathy [18].
There were no in vitro and in vivo studies that demon-
strated the possible mechanism of clevudine-associated
myopathy. The mechanisms of zidovudine-induced
myopathy have alluded that apoptosis of skeletal muscle
cells can be caused by direct mitochondrial DNA deple-
tion, mitochondrial dysfunction and oxidative stress,
and a depletion of L-carnitine [6]. It has been suggested
that zidovudine causes damage to mitochondria by
impairment of respiratory chain and mitochondrial
protein synthesis [19]. Because our cases showed no evi-
dence of mitochondrial damage on electron microscopic
ﬁnding, the mechanism of clevudine-induced muscle
damage might be oxidative stress, a depletion of any
substrate, or disturbance of protein synthesis, like alco-
hol or steroid-induced myopathies. Further in vitro and
vivo studies are needed to demonstrate the mechanism of
clevudine-induced myopathy.
Considering the structural similarity between clevu-
dine and telbivudine, myopathy that develops during
clevudine therapy may be regarded as clevudine-induced
and as a serious adverse event. There was a time lag of
six months between the onset of myopathic symptoms
and the cessation of clevudine treatment for Case 1.
Because of an inappropriate diagnosis of polymyositis,
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clevudine for a further two months. Case 2 had taken
clevudine for 13 months. She did not mention her gen-
eral weakness to the doctor until she was admitted to
the hospital for treatment of recurrent HCC. Although
proper management was delayed in our cases, cessation
of clevudine treatment resulted in amelioration of myo-
pathic symptoms and normalization of creatine kinase
levels.
In conclusion, during long-term clevudine treatment,
particular attention should be paid to muscular symp-
toms, and muscle enzyme levels should be monitored.
Any symptoms or signs associated with muscle damage
should be evaluated promptly. We report two cases of
drug-induced myopathy during clevudine therapy for
chronic hepatitis B. Further investigations are needed
to clarify the safety and eﬃcacy of long-term clevudine
therapy.
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